Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 49 entries
Sorted by: Best Match Show Resources per page
[Chemotherapy of lung cancer].

Voprosy onkologii

Vermel' AE, Sokolova GM.
PMID: 5333637
Vopr Onkol. 1965;11(9):106-14.

No abstract available.

Cite
Vermel' AE, Sokolova GM. Khimioterapiia rka legkogo. [Chemotherapy of lung cancer]. Vopr Onkol. 1965;11(9):106-14
Vermel', A. E., & Sokolova, G. M. (1965). Khimioterapiia rka legkogo. [Chemotherapy of lung cancer]. Voprosy onkologii, 11(9), 106-14.
Vermel', A E, and Sokolova, G M. "Khimioterapiia rka legkogo." [Chemotherapy of lung cancer]. Voprosy onkologii vol. 11,9 (1965): 106-14.
Vermel' AE, Sokolova GM. Khimioterapiia rka legkogo. [Chemotherapy of lung cancer]. Vopr Onkol. 1965;11(9):106-14. Russian. PMID: 5333637.
Copy Download .nbib Format: NLM
Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Masago K, Fujita S.
PMID: 34930606
J Thorac Oncol. 2022 Jan;17(1):16-18. doi: 10.1016/j.jtho.2021.10.002.

No abstract available.

Cite
Masago K, Fujita S. Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment. J Thorac Oncol. 2022;17(1):16-18doi: 10.1016/j.jtho.2021.10.002.
Masago, K., & Fujita, S. (2022). Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(1), 16-18. https://doi.org/10.1016/j.jtho.2021.10.002
Masago, Katsuhiro, and Fujita, Shiro. "Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 17,1 (2022): 16-18. doi: https://doi.org/10.1016/j.jtho.2021.10.002
Masago K, Fujita S. Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment. J Thorac Oncol. 2022 Jan;17(1):16-18. doi: 10.1016/j.jtho.2021.10.002. PMID: 34930606; PMCID: PMC8678031.
Copy Download .nbib Format: NLM
New molecularly targeted therapies for lung cancer.

The Journal of clinical investigation

Sun S, Schiller JH, Spinola M, Minna JD.
PMID: 17909619
J Clin Invest. 2007 Oct;117(10):2740-50. doi: 10.1172/JCI31809.

Lung cancer is the leading cause of cancer death worldwide. The disease is particularly difficult to detect, and patients often present at an advanced stage. Current treatments have limited effectiveness, and unfortunately, the prognosis remains poor. Recent insights into...

Cite
Sun S, Schiller JH, Spinola M, et al. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117(10):2740-50doi: 10.1172/JCI31809.
Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007). New molecularly targeted therapies for lung cancer. The Journal of clinical investigation, 117(10), 2740-50. https://doi.org/10.1172/JCI31809
Sun, Sophie, et al. "New molecularly targeted therapies for lung cancer." The Journal of clinical investigation vol. 117,10 (2007): 2740-50. doi: https://doi.org/10.1172/JCI31809
Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007 Oct;117(10):2740-50. doi: 10.1172/JCI31809. PMID: 17909619; PMCID: PMC1994616.
Copy Download .nbib Format: NLM
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.

Thoracic cancer

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I.
PMID: 30152594
Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28.

The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography...

Cite
Ide M, Tanaka K, Sunami S, et al. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2018;9(11):1519-1521doi: 10.1111/1759-7714.12853.
Ide, M., Tanaka, K., Sunami, S., Asoh, T., Maeyama, T., Tsuruta, N., Nakanishi, Y., & Okamoto, I. (2018). Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic cancer, 9(11), 1519-1521. https://doi.org/10.1111/1759-7714.12853
Ide, Maako, et al. "Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis." Thoracic cancer vol. 9,11 (2018): 1519-1521. doi: https://doi.org/10.1111/1759-7714.12853
Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28. PMID: 30152594; PMCID: PMC6209776.
Copy Download .nbib Format: NLM
[Mechanism of Ferroptosis and Its Research Progress in Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer

Wu J, Ma L, Wang J, Qiao Y.
PMID: 32758348
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):811-817. doi: 10.3779/j.issn.1009-3419.2020.104.16. Epub 2020 Aug 06.

Ferroptosis is a recently recognized form of regulated cell death caused by an iron-dependent accumulation of lipid reactive species. However, little research on ferroptosis and lung cancer, one of the most common tumors, has been carried out. This paper...

Cite
Wu J, Ma L, Wang J, et al. [Mechanism of Ferroptosis and Its Research Progress in Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2020;23(9):811-817doi: 10.3779/j.issn.1009-3419.2020.104.16.
Wu, J., Ma, L., Wang, J., & Qiao, Y. (2020). [Mechanism of Ferroptosis and Its Research Progress in Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 23(9), 811-817. https://doi.org/10.3779/j.issn.1009-3419.2020.104.16
Wu, Jinming, et al. "[Mechanism of Ferroptosis and Its Research Progress in Lung Cancer]." Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 23,9 (2020): 811-817. doi: https://doi.org/10.3779/j.issn.1009-3419.2020.104.16
Wu J, Ma L, Wang J, Qiao Y. [Mechanism of Ferroptosis and Its Research Progress in Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):811-817. doi: 10.3779/j.issn.1009-3419.2020.104.16. Epub 2020 Aug 06. Chinese. PMID: 32758348; PMCID: PMC7519954.
Copy Download .nbib Format: NLM
Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Simons EA, Smith DE, Gao D, Camidge DR.
PMID: 32353598
J Thorac Oncol. 2020 Sep;15(9):1425-1433. doi: 10.1016/j.jtho.2020.04.020. Epub 2020 Apr 27.

INTRODUCTION: Phase I and II trials provide the initial human safety and tolerability data for new drugs. Nevertheless, the methods for presenting toxicity data are not standardized. Clinicians often first encounter these data at professional conferences. We sought to...

Cite
Simons EA, Smith DE, Gao D, et al. Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences. J Thorac Oncol. 2020;15(9):1425-1433doi: 10.1016/j.jtho.2020.04.020.
Simons, E. A., Smith, D. E., Gao, D., & Camidge, D. R. (2020). Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(9), 1425-1433. https://doi.org/10.1016/j.jtho.2020.04.020
Simons, Emily A, et al. "Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 15,9 (2020): 1425-1433. doi: https://doi.org/10.1016/j.jtho.2020.04.020
Simons EA, Smith DE, Gao D, Camidge DR. Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences. J Thorac Oncol. 2020 Sep;15(9):1425-1433. doi: 10.1016/j.jtho.2020.04.020. Epub 2020 Apr 27. PMID: 32353598; PMCID: PMC7667578.
Copy Download .nbib Format: NLM
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer

Huang B, Duan Y.
PMID: 31014443
Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.

With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis...

Cite
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019;22(4):239-244doi: 10.3779/j.issn.1009-3419.2019.04.07.
Huang, B., & Duan, Y. (2019). [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 22(4), 239-244. https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang, Benlin, and Duan, Yong. "[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]." Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 22,4 (2019): 239-244. doi: https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07. Chinese. PMID: 31014443; PMCID: PMC6500500.
Copy Download .nbib Format: NLM
Proposal for a new section in Lung Cancer on ongoing randomized trials.

Lung cancer (Amsterdam, Netherlands)

Pignon JP, Arriagada R.
PMID: 7704497
Lung Cancer. 1994 Dec;11(5):401-3. doi: 10.1016/0169-5002(94)92169-5.

No abstract available.

Cite
Pignon JP, Arriagada R. Proposal for a new section in Lung Cancer on ongoing randomized trials. Lung Cancer. 1994;11(5):401-3doi: 10.1016/0169-5002(94)92169-5.
Pignon, J. P., & Arriagada, R. (1994). Proposal for a new section in Lung Cancer on ongoing randomized trials. Lung cancer (Amsterdam, Netherlands), 11(5), 401-3. https://doi.org/10.1016/0169-5002(94)92169-5
Pignon, J P, and Arriagada, R. "Proposal for a new section in Lung Cancer on ongoing randomized trials." Lung cancer (Amsterdam, Netherlands) vol. 11,5 (1994): 401-3. doi: https://doi.org/10.1016/0169-5002(94)92169-5
Pignon JP, Arriagada R. Proposal for a new section in Lung Cancer on ongoing randomized trials. Lung Cancer. 1994 Dec;11(5):401-3. doi: 10.1016/0169-5002(94)92169-5. PMID: 7704497.
Copy Download .nbib Format: NLM
What were the issues of surgical importance in lung cancer treatment in 1977? How did they change over time?.

Chest

McKneally MF.
PMID: 7988245
Chest. 1994 Dec;106(6):283S-286S.

The LCSG tested innovative and standard adjuvant treatments aimed at strengthening the effectiveness of surgical resection. The group addressed issues related to standardizing and improving surgical treatment, and the perioperative use of chemotherapy, radiotherapy, and immunotherapy alone and in...

Cite
McKneally MF. What were the issues of surgical importance in lung cancer treatment in 1977? How did they change over time?. Chest. 1994;106(6):283S-286S
McKneally, M. F. (1994). What were the issues of surgical importance in lung cancer treatment in 1977? How did they change over time?. Chest, 106(6), 283S-286S.
McKneally, M F. "What were the issues of surgical importance in lung cancer treatment in 1977? How did they change over time?." Chest vol. 106,6 (1994): 283S-286S.
McKneally MF. What were the issues of surgical importance in lung cancer treatment in 1977? How did they change over time?. Chest. 1994 Dec;106(6):283S-286S. PMID: 7988245.
Copy Download .nbib Format: NLM
Lessons from considering the cancer landscape.

Oncology (Williston Park, N.Y.)

Mulshine JL.
PMID: 25184263
Oncology (Williston Park). 2013 May;27(5):408, 410.

No abstract available.

Cite
Mulshine JL. Lessons from considering the cancer landscape. Oncology (Williston Park). 2013;27(5):408, 410
Mulshine, J. L. (2013). Lessons from considering the cancer landscape. Oncology (Williston Park, N.Y.), 27(5), 408, 410.
Mulshine, James L. "Lessons from considering the cancer landscape." Oncology (Williston Park, N.Y.) vol. 27,5 (2013): 408, 410.
Mulshine JL. Lessons from considering the cancer landscape. Oncology (Williston Park). 2013 May;27(5):408, 410. PMID: 25184263.
Copy Download .nbib Format: NLM
Lung Cancer, Covid-19 Infections and Chemotherapy.

In vivo (Athens, Greece)

Haineala B, Zgura A, Badiu DC, Iliescu L, Anghel RM, Bacinschi XE.
PMID: 33910875
In Vivo. 2021 May-Jun;35(3):1877-1880. doi: 10.21873/invivo.12450.

BACKGROUND/AIM: The Covid-19 epidemic has severely strained health care systems across the globe. The impacts are multiple especially for patients cared for cancer. The Covid-19 epidemic has several impacts on the management of lung cancer patients. The aim of...

Cite
Haineala B, Zgura A, Badiu DC, et al. Lung Cancer, Covid-19 Infections and Chemotherapy. In Vivo. 2021;35(3):1877-1880doi: 10.21873/invivo.12450.
Haineala, B., Zgura, A., Badiu, D. C., Iliescu, L., Anghel, R. M., & Bacinschi, X. E. (2021). Lung Cancer, Covid-19 Infections and Chemotherapy. In vivo (Athens, Greece), 35(3), 1877-1880. https://doi.org/10.21873/invivo.12450
Haineala, Bogdan, et al. "Lung Cancer, Covid-19 Infections and Chemotherapy." In vivo (Athens, Greece) vol. 35,3 (2021): 1877-1880. doi: https://doi.org/10.21873/invivo.12450
Haineala B, Zgura A, Badiu DC, Iliescu L, Anghel RM, Bacinschi XE. Lung Cancer, Covid-19 Infections and Chemotherapy. In Vivo. 2021 May-Jun;35(3):1877-1880. doi: 10.21873/invivo.12450. PMID: 33910875; PMCID: PMC8193347.
Copy Download .nbib Format: NLM
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.

Lung cancer (Amsterdam, Netherlands)

Quist M, Langer SW, Lillelund C, Winther L, Laursen JH, Christensen KB, Rørth M, Adamsen L.
PMID: 32416432
Lung Cancer. 2020 Jul;145:76-82. doi: 10.1016/j.lungcan.2020.05.003. Epub 2020 May 08.

OBJECTIVE: Exercise can improve treatment-related side effects, quality of life, and function in patients with various types of cancer; however, more evidence is needed for patients with advanced inoperable lung cancer.MATERIAL AND METHODS: We randomized 218 patients with advanced...

Cite
Quist M, Langer SW, Lillelund C, et al. Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer. 2020;145:76-82doi: 10.1016/j.lungcan.2020.05.003.
Quist, M., Langer, S. W., Lillelund, C., Winther, L., Laursen, J. H., Christensen, K. B., Rørth, M., & Adamsen, L. (2020). Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung cancer (Amsterdam, Netherlands), 14576-82. https://doi.org/10.1016/j.lungcan.2020.05.003
Quist, Morten, et al. "Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial." Lung cancer (Amsterdam, Netherlands) vol. 145 (2020): 76-82. doi: https://doi.org/10.1016/j.lungcan.2020.05.003
Quist M, Langer SW, Lillelund C, Winther L, Laursen JH, Christensen KB, Rørth M, Adamsen L. Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer. 2020 Jul;145:76-82. doi: 10.1016/j.lungcan.2020.05.003. Epub 2020 May 08. PMID: 32416432.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 49 entries